BACE1 and Alzheimer disease: Caccamo et al. (2006) investigated the therapeutic efficacy of selective M1 mAChR agonist AF267B in the 3 × Tg-AD model mice (human APP Swedish mutation, APPSwe, tauP30L, mutant PS1M146V knockin) and found a significant decrease in BACE1 levels in the brain of AF267B treated mice vs. untreated 3 × Tg-AD mice.